Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 8/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557620 | 0.94 | SLC16A3 (0.56) | SLC16A3RAB9AAKR1C3KDM4ETSHR | |
| SCHEMBL3558201 | 0.89 | SLC16A3 (0.58) | SLC16A3RAB9AKDM4EKMT2ANPSR1 | |
| SCHEMBL3554444 | 0.87 | THRB (0.52) | SLC16A3AKR1C3KMT2ANPSR1THRB | |
| SCHEMBL3556908 | 0.86 | MEN1 (0.48) | SLC16A3RAB9AAKR1C3KMT2ANPSR1 | |
| SCHEMBL3553033 | 0.86 | NPSR1 (0.45) | SLC16A3RAB9AKDM4EKMT2ANPSR1 | |
| SCHEMBL3551762 | 0.83 | SLC16A3 (0.53) | SLC16A3RAB9AKDM4EKMT2ANPSR1 | |
| SCHEMBL3552744 | 0.83 | SLC16A3 (0.85) | SLC16A3RAB9AAKR1C3KDM4ETSHR | |
| SCHEMBL3552311 | 0.83 | HTR6 (0.44) | SLC16A3NPSR1THRB | |
| SCHEMBL3552840 | 0.82 | NPSR1 (0.43) | SLC16A3KMT2ANPSR1 | |
| SCHEMBL3561549 | 0.82 | SLC16A3 (0.63) | SLC16A3RAB9AAKR1C3KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | SLC16A3 425/4885RAB9A 4528/4885AKR1C3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.